Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease

Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...

詳細記述

書誌詳細
主要な著者: Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar
フォーマット: 論文
言語:English
出版事項: Frontiers Media S.A. 2021-10-01
シリーズ:Frontiers in Chemistry
主題:
オンライン・アクセス:https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full